2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-ethanone | 364066-98-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-ethanone
• 英文别名: 2-(2-amino-4-chlorophenoxy)-1-[(2R,5S)-4-[(4-fluorophenyl)methyl]-2,5-dimethylpiperazin-1-yl]ethanone
• CAS: 364066-98-8
• 化学式: C₂₁H₂₅ClFN₃O₂
• 分子量: 405.9
• InChiKey: MMUYKPOLYWHQLP-LSDHHAIUSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  28
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  58.8
• 氢给体数：
  1
• 氢受体数：
  5

反应信息

• 作为反应物：
  描述：

  2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-ethanone 、 对硝基苯基氯甲酸酯 在 吡啶 作用下， 以 二氯甲烷 为溶剂， 生成 (2R,5S)-(5-chloro-2-[2-[4-(4-fluoro-benzyl)-2,5-dimethyl-piperazin-1-yl]-2-oxo-ethoxy]-phenyl)-carbamic acid 4-nitro-phenyl ester
  参考文献：
  名称：

  Piperazinyl CCR1 antagonists—optimization of human liver microsome stability

  摘要：

  The synthesis, biological activity, and pharmacokinetic profile of CCR1 antagonists are described. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.037
• 作为产物：
  描述：

  2-(4-chloro-2-nitro-phenoxy)-1-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-ethanone 在 PtO₂/C 氢气 作用下， 以 乙醇 为溶剂， 20.0 ℃ 、241.32 kPa 条件下， 生成 2-(2-amino-4-chloro-phenoxy)-1-[4-(4-fluoro-benzyl)-(2R,5S)-2,5-dimethyl-piperazin-1-yl]-ethanone
  参考文献：
  名称：

  Piperazinyl CCR1 antagonists—optimization of human liver microsome stability

  摘要：

  The synthesis, biological activity, and pharmacokinetic profile of CCR1 antagonists are described. (C) 2007 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2007.03.037

文献信息

• Methods of using piperazine derivatives
  申请人：Pfizer Inc

  公开号：US20040092529A1

  公开（公告）日：2004-05-13

  The present invention relates to compounds of the formula I 1 and the pharmaceutically acceptable forms thereof; wherein X, Y, a, b, c, d, R 1 , R 2 , R 3 , R 4 and R 5 are as defined herein. Moreover, the present invention is also directed at pharmaceutical compositions comprising a compound of the formula I and a pharmaceutically acceptable carrier. Furthermore, the present invention is directed at methods of using the herein described compounds and compositions for treating or preventing a disorder or condition that can be treated or prevented by antagonizing the CCR1 receptor in a mammal.

  本发明涉及公式I1的化合物及其药学上可接受的形式；其中X、Y、a、b、c、d、R1、R2、R3、R4和R5如本文所定义。此外，本发明还涉及包含公式I的化合物和药学上可接受的载体的药物组合物。此外，本发明还涉及使用本文所述的化合物和组合物治疗或预防哺乳动物中可通过拮抗CCR1受体治疗或预防的疾病或状况的方法。
• Novel piperazine derivatives
  申请人：——

  公开号：US20020107255A1

  公开（公告）日：2002-08-08

  A compound of the formula 1 or the pharmaceutically acceptable salt thereof; wherein a, b, c, d, e, j, R 1 , R 2 , R 3 , and R 4 are as defined above useful to treat inflammation and other immune disorders.

  公式1的化合物或其药学上可接受的盐；其中a，b，c，d，e，j，R1，R2，R3和R4如上所定义，用于治疗炎症和其他免疫性疾病。
• Piperazine derivatives
  申请人：Pfizer, Inc.

  公开号：US06649611B2

  公开（公告）日：2003-11-18

  A compound of the formula or the pharmaceutically acceptable salt thereof; wherein a, b, c, d, e, j, R1, R2, R3, and R4 are as defined herein and are useful to treat inflammation and other immune disorders.

  该化合物的公式或其药学上可接受的盐；其中a、b、c、d、e、j、R1、R2、R3和R4如本文所定义，可用于治疗炎症和其他免疫性疾病。
• Piperazine urea derivatives for the treatment of endometriosis
  申请人：Kaufmann Ulrike

  公开号：US20080119471A1

  公开（公告）日：2008-05-22

  Use of a compound of the following formula (Ia): for the production of a medicament for the treatment of endometriosis in human wherein the treatment comprises administering to a human female in need of such treatment a therapeutically effective amount of said compound.

  使用以下化学式（Ia）的化合物制备治疗人类子宫内膜异位症的药物，其中治疗包括向需要此类治疗的女性人体内给予治疗有效量的该化合物。
• Chemokine inhibiting piperazine derivatives and their use to treat myocarditis
  申请人：Futamatsu Hideki

  公开号：US20050043318A1

  公开（公告）日：2005-02-24

  The present invention relates to piperazine derivatives of formulae Ia, Ib, Ic and Id and their use to treat myocarditis. where R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 and Y are as defined herein.

  本发明涉及式 Ia、Ib、Ic 和 Id 的哌嗪衍生物及其治疗心肌炎的用途。 其中 R 1a , R 1b , R 2 , R 3 , R 4 , R 5 , R 6 , R 9 , R 10 和 Y 如本文所定义。